Charles River Labs (CRL) Stock Price & Analysis
CRL Stock Chart & Stats
- Day’s Range
- MXN 6,559.90 - MXN 6,559.90
- 52-Week Range
- MXN 3,132.64 - MXN 6,559.90
- Previous Close
- MXN 6,559.90
- Volume
- 26
- Average Volume (3M)
- 3
- Market Cap
- MXN 322.43B
- Enterprise Value
- MXN 13.23B
- Total Cash (Recent Filing)
- MXN 192.03M
- Total Debt (Recent Filing)
- MXN 3.03B
- Price to Earnings (P/E)
- ―
- Beta
- -0.21
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- 55.83
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
DSA Demand
Stronger bookings, backlog, and book-to-bill indicate improving demand for Charles River’s discovery and safety services. These indicators support revenue visibility over the next several quarters and reinforce the company’s role in customers’ preclinical development programs.
Cash Generation
Positive operating and free cash flow show that the business continues to convert activity into cash despite reported losses. This provides funding for operations, investment, debt service, and strategic initiatives while earnings recovery remains in progress.
Efficiency Strategy
The multi-year efficiency program and investment in AI, automation, and laboratory capabilities could improve scalability and margins beyond the current recovery. A defined savings target also gives management a durable framework for strengthening competitiveness and profitability.
Bears Say
Profitability Decline
The shift from double-digit net margins in earlier years to losses materially weakens current earnings power. Sustained profitability recovery will be necessary to restore financial resilience, support reinvestment, and demonstrate that recent margin actions are durable.
Leverage
Meaningful leverage reduces financial flexibility while earnings are under pressure. Debt service and refinancing needs can compete with investment and shareholder returns, making the balance sheet more sensitive to any prolonged weakness in operating performance.
RMS Weakness
Weakness in Research Models and Services reflects lower North American volumes and remains a drag on the company’s diversified platform. Continued declines could offset growth in DSA and Manufacturing, limiting consolidated revenue recovery over the next several quarters.
Charles River Labs News
CRL FAQ
What was Charles River Labs’s price range in the past 12 months?
What is Charles River Labs’s market cap?
When is Charles River Labs’s upcoming earnings report date?
How were Charles River Labs’s earnings last quarter?
Is Charles River Labs overvalued?
Does Charles River Labs pay dividends?
What is Charles River Labs’s EPS estimate?
How many shares outstanding does Charles River Labs have?
What happened to Charles River Labs’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Charles River Labs?
What is the TipRanks Smart Score and how is it calculated?
Charles River Labs Stock Smart Score
Company Description
Charles River Labs
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Birgit Girshick
- Employees
- 19,000
- Website
- www.criver.com
- Address
- 251 Ballardvale Street, Wilmington, MA, 01887, US
Charles River Labs (CRL) Earnings & Revenues
CRL Company Deck
CRL Earnings Call
Earnings Call SentimentPositive
The call highlighted clear operational progress: better-than-expected Q2 results, sequential margin improvement (420 bps), stronger DSA demand signals with bookings/backlog gains and raised full-year guidance (organic revenue guidance improved by ~150 bps and EPS guidance raised). Strategic actions (divestitures, NHP supply integration, partnerships, AI/digital investments and lab expansions) are positioned to drive further margin and growth upside. However, notable near-term challenges remain: RMS softness driven by North American academic/government funding constraints, Q2 free cash flow decline, higher corporate costs and an elevated tax rate headwind, plus timing risk with material NHP sourcing benefits largely back-loaded into Q4 and pricing improvements not yet realized. On balance, positives (outperformance, raised guidance, bookings/backlog strength, margin momentum and strategic partnerships) outweigh the lowlights, though some operational and timing risks persist.
View all MX:CRL earnings summariesCRL Net sales Breakdown
- 21.07% RMS
- 59.84% DSA
- 19.09% Manufacturing
CRL Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 1 | 6 |
| Technical Analysis | 2 | 1 | 6 |
| Moving Averages | 12 | 0 | 0 |
